Adjuvant hormonal therapy in premenopausal women with breast cancer

Duration of tamoxifen Tamoxifen use was truncated at 5 years based on the National Surgical Adjuvant Breast and Bowel Project (NSABP) B14 study. While this trial initially showed that 5 years of treatment was effective as compared to no-tamoxifen for hormone receptor positive, node negative breast cancer (mostly postmenopausal), a re-randomization of the treated cohort suggested that 10 years of therapy could be inferior to five.[9,10] This observation guided practice globally.

• Publication year

  2015

• Venue

  Indian Journal of Medical and Paediatric Oncology

• Publication date

  2015-10-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.4103/0971-5851.171530PMID 26811586PMCID 4711215
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Dexamethasone and supportive care with or without whole brain radiotherapy in treating patients with non-small cell lung cancer with brain metastases unsuitable for resection or stereotactic radiotherapy (QUARTZ): results from a phase 3, non-inferiority, randomised trial

  2016influential reference
• Adjuvant ovarian suppression in premenopausal breast cancer.

  2015influential reference
• Zoledronic acid combined with adjuvant endocrine therapy of tamoxifen versus anastrozol plus ovarian function suppression in premenopausal early breast cancer: final analysis of the Austrian Breast and Colorectal Cancer Study Group Trial 12.

  2015cited by this paper
• Adjuvant endocrine therapy for women with hormone receptor-positive breast cancer: american society of clinical oncology clinical practice guideline focused update.

  2014cited by this paper
• Optimal management of the premenopausal patient with estrogen receptor-positive breast cancer.

  2014cited by this paper
• Adjuvant exemestane with ovarian suppression in premenopausal breast cancer.

  2014influential reference
• aTTom: Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years in 6,953 women with early breast cancer.

  2013cited by this paper
• Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomised trial

  2013cited by this paper
• Impact of premenopausal status at breast cancer diagnosis in women entered on the placebo-controlled NCIC CTG MA17 trial of extended adjuvant letrozole.

  2013cited by this paper
• Hormonal therapies in young breast cancer patients: when, what and for how long?

  2013cited by this paper
• GLOBOCAN 2012 v1.0, Cancer Incidence and Mortality Worldwide: IARC Cancer Base No. 11 [Internet]

  2013cited by this paper
• Optimal systemic therapy for premenopausal women with hormone receptor-positive breast cancer.

  2013cited by this paper
• Impact of body mass index on the efficacy of endocrine therapy in premenopausal patients with breast cancer: an analysis of the prospective ABCSG-12 trial.

  2011cited by this paper
• Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials

  2011cited by this paper
• Adjuvant endocrine therapy in premenopausal women with breast cancer

  2010influential reference
• Longer therapy, iatrogenic amenorrhea, and survival in early breast cancer.

  2010cited by this paper
• Late extended adjuvant treatment with letrozole improves outcome in women with early-stage breast cancer who complete 5 years of tamoxifen.

  2008cited by this paper
• Intent-to-treat analysis of the placebo-controlled trial of letrozole for extended adjuvant therapy in early breast cancer: NCIC CTG MA.17.

  2008cited by this paper
• Use of luteinising-hormone-releasing hormone agonists as adjuvant treatment in premenopausal patients with hormone-receptor-positive breast cancer: a meta-analysis of individual patient data from randomised adjuvant trials.

  2007cited by this paper
• Efficacy of letrozole extended adjuvant therapy according to estrogen receptor and progesterone receptor status of the primary tumor: National Cancer Institute of Canada Clinical Trials Group MA.17.

  2007cited by this paper
• Amenorrhea in premenopausal women after adjuvant chemotherapy for breast cancer.

  2006cited by this paper
• Tamoxifen after adjuvant chemotherapy for premenopausal women with lymph node-positive breast cancer: International Breast Cancer Study Group Trial 13-93.

  2006cited by this paper
• The biology of steroid hormones and endocrine treatment of breast cancer.

  2005cited by this paper
• Incidence and prognostic impact of amenorrhea during adjuvant therapy in high-risk premenopausal breast cancer: analysis of a National Cancer Institute of Canada Clinical Trials Group Study--NCIC CTG MA.5.

  2005cited by this paper
• Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials.

  2005cited by this paper
• Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years' adjuvant treatment for breast cancer.

  2005cited by this paper
• Chemoendocrine therapy for premenopausal women with axillary lymph node-positive, steroid hormone receptor-positive breast cancer: results from INT 0101 (E5188).

  2005cited by this paper
• A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer.

  2005cited by this paper
• Cancer Facts & Figures 2004

  2004cited by this paper
• Steroid hormone receptors in breast cancer management

  2004cited by this paper
• A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer.

  2004cited by this paper
• Adjuvant hormonal therapy for premenopausal women with breast cancer.

  2003cited by this paper
• Adjuvant chemotherapy followed by goserelin versus either modality alone for premenopausal lymph node-negative breast cancer: a randomized trial.

  2003cited by this paper
• Estrogen Receptor Breast Cancer Phenotypes in the Surveillance, Epidemiology, and End Results Database

  2002cited by this paper
• Five versus more than five years of tamoxifen for lymph node-negative breast cancer: updated findings from the National Surgical Adjuvant Breast and Bowel Project B-14 randomized trial.

  2001cited by this paper
• Ovarian ablation in breast cancer, 1896 to 1998: milestones along hierarchy of evidence from case report to Cochrane review

  1998cited by this paper
• Prognostic impact of amenorrhoea after adjuvant chemotherapy in premenopausal breast cancer patients with axillary node involvement: results of the International Breast Cancer Study Group (IBCSG) Trial VI.

  1998cited by this paper
• Polychemotherapy for early breast cancer: an overview of the randomised trials. Early Breast Cancer Trialists' Collaborative Group.

  1998influential reference
• Ovarian ablation in early breast cancer: overview of the randomised trials. Early Breast Cancer Trialists' Collaborative Group.

  1996cited by this paper
• Five versus more than five years of tamoxifen therapy for breast cancer patients with negative lymph nodes and estrogen receptor-positive tumors.

  1996cited by this paper
• Ovarian ablation in early breast cancer: Overview of the randomised trials

  1996cited by this paper
• The value of estrogen and progesterone receptors in the treatment of breast cancer

  1980cited by this paper
• Clinical trials in malignant disease. Part II-breast cancer: value of irradiation of the ovaries.

  1959cited by this paper
• Cáncer

  1939cited by this paper
• On the Treatment of Inoperable Cases of Carcinoma of the Mamma: Suggestions for a New Method of Treatment, with Illustrative Cases

  1896cited by this paper

• Neuropsychological assessment, intervention, and best practices for women with non-Central nervous system cancer: A scoping review of current standards

  2024cites this paper
• Development and Validation for the Estimation of Assay and Forced Degradation Impurities of Goserelin Acetate Sustained-Release Implant Using HPLC and LC–MS

  2023cites this paper
• In silico approach and molecular docking studies of potent bioactive compounds of Carica papaya as anti-breast cancer agents.

  2022cites this paper
• Targeting ERα degradation by L-Tetrahydropalmatine provides a novel strategy for breast cancer treatment

  2020cites this paper
• Genome Instability Profiles Predict Disease Outcome in a Cohort of 4,003 Patients with Breast Cancer

  2020cites this paper
• Breast cancer: insights in disease and influence of drug methotrexate.

  2020cites this paper
• Targeting the Key Signaling Pathways in Breast Cancer Treatment Using Natural Agents

  2020cites this paper
• ERα is a target for butein-induced growth suppression in breast cancer.

  2020cites this paper
• Reproductive factors and breast cancer risk: A meta-analysis of case–control studies in Indian women

  2019cites this paper
• Cognizance and utilization about breast cancer screening among the health professional female students and staffs of University Kuala Lumpur, Royal College of Medicine Perak, Malaysia

  2016cites this paper
• HOXB7 Is an ERα Cofactor in the Activation of HER2 and Multiple ER Target Genes Leading to Endocrine Resistance.

  2015cites this paper
• A pivotal role for HOXB7 protein in endocrine resistant breast cancer

  2015cites this paper
• Fertility after breast cancer treatment.

  2014cites this paper
• The atypical ubiquitin ligase RNF31 stabilizes estrogen receptor α and modulates estrogen-stimulated breast cancer cell proliferation

  2014cites this paper
• Phytoestrogenic extracts of Cyclopia modulate molecular targets involved in the prevention and treatment of breast cancer

  2014cites this paper
• Oestrogen receptors in breast cancer: basic mechanisms and clinical implications

  2013cites this paper